During the past decade, Leuven Cancer Institute conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Leuven Cancer Institute" are "Diffuse Large B Cell Lymphoma" (1 trials), "GIST" (1 trials), "Gastric Adenocarcinoma" (1 trials), "Gastroesophageal Junction Adenocarcinoma" (1 trials) and "Hodgkin Lymphoma" (1 trials). Many other conditions were trialed in "Leuven Cancer Institute" in a lesser frequency.

Most popular intervention types in "Leuven Cancer Institute" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "SL-279252" (1 trials), "avapritinib" (1 trials) and "regorafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Leuven Cancer Institute" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Leuven Cancer Institute". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Leuven Cancer Institute, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Leuven Cancer Institute, 1 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".